AUTHOR=Dai Minqian , Wang Na , Xia Qin , Liao Yongde , Cao Wei , Fan Jun , Zhou Diwei , Wang Sihua , Nie Xiu 

TITLE=Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report

JOURNAL=Frontiers in Immunology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1258762

DOI=10.3389/fimmu.2023.1258762

ISSN=1664-3224

ABSTRACT=<p>Neoadjuvant chemoimmunotherapy has demonstrated significant benefit for resectable non-small-cell lung cancer (NSCLC) excluding known <italic>EGFR/ALK</italic> genetic alterations. Recent evidence has shown that neoadjuvant chemoimmunotherapy could be clinically valuable in resectable localized driver gene-mutant NSCLC, though the data still lack robust support, especially for rare oncogenic mutations. Here, we report a patient with stage IIIA lung adenocarcinoma with a <italic>RET</italic> fusion gene and high expression of PD-L1 who underwent neoadjuvant chemoimmunotherapy and successfully attained a pathologic complete response. The patient has survived for 12 months with no recurrence or metastases after surgery. Our case suggests that this treatment strategy may be an alternative therapeutic option for resectable <italic>RET</italic> fusion-positive NSCLC patients.</p>